Literature DB >> 19893772

The identification of Lynch syndrome in British Columbia.

Carol M Cremin1, Linlea Armstrong, Sharlene Gill, David Huntsman, Chris Bajdik.   

Abstract

OBJECTIVE: To determine the prevalence of Lynch syndrome mutations in a Canadian hereditary cancer clinic population, and to determine the effectiveness of the program's referral criteria and testing algorithm.
METHODS: A retrospective chart review of all patients who were referred for and received genetic counselling at the BC Cancer Agency's Hereditary Cancer Program for a family history of colon cancer from August 1, 2004, to September 1, 2006, was performed. Charts were reviewed for referral criteria met, cancer history, whether testing was offered and the outcome of testing.
RESULTS: Lynch syndrome was confirmed or highly suspected in 14.3% of index test patients (eight of 56) by the identification of a deleterious mutation or variant likely to be deleterious in either of the hMLH1 or hMSH2 mismatch repair genes. In the program, the two most effective criteria were a personal diagnosis of two or more primary Lynch syndrome-related cancers (one diagnosed at younger than 50 years of age) or two first-degree relatives with a Lynch syndrome-related cancer (both diagnosed at younger than 50 years of age). The respective positive predictive values of these two criteria were calculated to be 66.7% (95% CI 40% to 93%) and 58.3% (95% CI 30.4% to 86.2%).
CONCLUSIONS: The Hereditary Cancer Program developed and successfully implemented an approach that selected individuals at risk for Lynch syndrome with a significant pretest probability of mutation of 14.3%. Improved ascertainment of families with Lynch syndrome will require greater physician awareness of referral criteria, program advances in the testing algorithm and a population-based approach to screening incident colon cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893772      PMCID: PMC2777089          DOI: 10.1155/2009/620518

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  28 in total

1.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).

Authors:  H F Vasen; J P Mecklin; P M Khan; H T Lynch
Journal:  Dis Colon Rectum       Date:  1991-05       Impact factor: 4.585

Review 2.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

3.  Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.

Authors:  C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

4.  Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1.

Authors:  S Syngal; E A Fox; C Eng; R D Kolodner; J E Garber
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

5.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

6.  Predicting the performance of a genetic testing service for cancer susceptibility.

Authors:  Chris D Bajdik; Steve Sung; John J Spinelli; David Huntsman; Steven Gallinger; Douglas Horsman; Richard P Gallagher
Journal:  Genet Test       Date:  2007

7.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

8.  Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis.

Authors:  W Kievit; J H F M de Bruin; E M M Adang; M J L Ligtenberg; F M Nagengast; J H J M van Krieken; N Hoogerbrugge
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

9.  Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients.

Authors:  L A Aaltonen; P Peltomäki; J P Mecklin; H Järvinen; J R Jass; J S Green; H T Lynch; P Watson; G Tallqvist; M Juhola
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

View more
  2 in total

1.  Efficacy of an educational intervention on family physicians' risk assessment and management of colorectal cancer.

Authors:  J C Carroll; S Blaine; J Permaul; E Dicks; E Warner; M J Esplen; H Rothenmund; K Semotiuk; G Worrall; J McLaughlin
Journal:  J Community Genet       Date:  2014-04-09

2.  Recognition of Lynch Syndrome Amongst Newly Diagnosed Colorectal Cancers at St. Paul's Hospital.

Authors:  Steven Pi; Estello Nap-Hill; Jennifer Telford; Robert Enns
Journal:  Can J Gastroenterol Hepatol       Date:  2017-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.